Search

Objective: To clone a gametocyte specific protein Pfgdv1 of Plasmodium falciparum, express and identify recombinant Pfgdvl protein in vitro., Methods: PCR was performed to amplify Pfgdv1 from P. falciparum DNA which was got from the patient who was infected with P. falciparum, and the PCR product was inserted into pET28a (+) vector. pET28a-Pfgdv1 recombinant plasmid was constructed and transformed into E. coli host BL21 (DE3+). IPTG was used to induce the recombinant Pfgdv1 protein fused with His tag, and the protein was purified by His-NTA affinity chromatography. The recombinant protein was identified by SDS-PAGE and Western blotting., Results: The PCR product of Pfgdv1 gene was about 1.65 kb, meeting the expectation of predicted fragment size. The recombinant protein was about 67 kDa, which could be recognized by His-Tag monoclonal antibody., Conclusion: The Pfgdv1 gene of P. falciparum is successfully cloned, and the recombinant Pfgdv1 protein is expressed, thereby providing an opportunity for further study on transmission blocking vaccine.

Objective: To construct recombinant Mycobacterium smegmatis vaccine expressing Cysticercus cellulosae cC1 antigen., Methods: The recombinant pET28a-cC1 plasmid was extracted and double digested by Xho I and BamH I restriction enzymes, and shuttle plasmid pMV261 was extracted and double digested by Hind III and BamH I restriction enzymes. Both fragments were modified by Klenow fragment to form blunt end, then the large fragments of cC1 and pMV261 plasmid were purified and ligated by T4 ligase enzyme. The recombinant pMV261-cC1 plasmid was constructed and sequenced. Then the pMV261-cC1 plasmid was transformed into Mycobacterium smegmatis by the electrotransformation method. The recombinant cC1-Mycobacterium smegmatis was induced by heat and identified by the Western blotting method with the sera of cysticercosis patients. In addition, the growth states of the Mycobacterium smegmatis and the recombinant cC1-Mycobacterium smegmatis were compared and the growth curves were drawn., Results: The restriction enzyme and sequencing results showed that the recombinant pMV261-cC1 plasmid was successfully constructed. After heat induction, a 40 kD band was showed by PAGE analysis of cC1-Mycobacterium smegmatis. The Western blotting results showed that the sera of cysticercosis patients could recognize the 40 kDa band, which suggested that cC1 protein was expressed in Mycobacterium smegmatis. Compared with the Mycobacterium smegmatis, the recombi- nant cC1-Mycobacterium smegmatis showed no significant difference in proliferation characteristics., Conclusion: The recombinant cC1-Mycobacterium smegmatis vaccine has been successfully constructed.

Malaria remains a serious public health problem, especially in developing countries. With the deepening of the understanding of vivax malaria, Plasmodium vivax is also attracting more and more attention. An effective drug treatment is the foundation of controlling or even eliminating malaria. In recent years, more and more reports of chloroquine-resistance Plasmodium vivax have been reported. Plasmodium vivax chloroquine resistance has been a focus problem in vivax malaria prevention and treatment. In this paper, the research progress on distribution situation, detection methods and molecular markers of Plasmodium vivax chloroquine resistance is summarized.